このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Feasibility and Effects of a Realistic Stressful Virtual Environment on Balance and Mobility in Healthy Adults: A Pilot Study

2026年11月5日 更新者:Vrije Universiteit Brussel

Does a Real-life Stressful Virtual Environment Change Balance and Mobility Performance? A Pilot Feasibility Study

The goal of this pilot clinical trial is to evaluate the feasibility of a new approach to assessing balance and mobility in everyday situations by performing established clinical tests in a stressful virtual reality environment. The study involves healthy adults aged 18 years and older with no self-reported neurological disorders or history of epilepsy.

The main questions it aims to answer are:

  1. Is it feasible to perform standard balance and mobility tests in a virtual reality environment simulating a busy train station?
  2. How does this virtual environment affect participants' balance and mobility test performance?
  3. How do participants experience the virtual environment, including their sense of being there and any discomfort or virtual reality sickness?

Researchers will compare each participant's performance with and without virtual reality to see if the virtual environment changes balance and mobility test results.

Participants will:

  • Spend a brief familiarisation period in the virtual environment before testing.
  • Complete the Mini-BESTest, which assesses balance through a series of tasks, with and without virtual reality.
  • Complete the Timed Up and Go test, which involves standing up from a chair, walking three meters, turning, returning, and sitting down, with and without virtual reality and with and without counting backwards by threes.
  • Complete the 10-Meter Walk Test at comfortable and fast walking speeds, with and without virtual reality.
  • Complete questionnaires after the final virtual reality exposure about their sense of being in the virtual environment and any symptoms of discomfort or sickness.

調査の概要

研究の種類

介入

入学 (実際)

11

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • healthy adults aged 18 years and older

Exclusion Criteria:

  • self-reported neurological disorders
  • history of epilepsy

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Balance and mobility assessment with and without virtual reality

All participants complete the Mini-BESTest, Timed Up and Go test, and 10-Meter Walk Test both without a virtual reality headset and while wearing a headset displaying a busy virtual train station. The Timed Up and Go test is performed with and without an additional cognitive task in each condition.

Participants wear a standalone virtual reality headset (Meta Quest 3) displaying a busy train-station environment while completing standard balance and mobility assessments. The environment includes moving pedestrians, animated displays, and recorded train-station sounds. Participants undergo a brief familiarisation period before testing.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportion of participants completing all planned assessments
時間枠:At the end of the single assessment session on Day 1, after completion or discontinuation of the planned assessments.

Proportion of participants who complete all planned assessments in both non-virtual reality (noVR) and virtual reality (VR) conditions. The predefined feasibility criterion is completion by at least 80% of participants.

At the end of the single assessment session on Day 1, after completion or discontinuation of the planned assessments.
Number of virtual reality-related technical issues
時間枠:From the start of virtual reality system setup to the end of the virtual reality assessments during the single assessment session on Day 1.

technical feasibility: assessed by the number and type of VR-related technical issues encountered

From the start of virtual reality system setup to the end of the virtual reality assessments during the single assessment session on Day 1.
Proportion of complete outcome measurements per test and condition
時間枠:Data recording during all planned tests in the virtual reality and non-virtual reality conditions within the single assessment session on Day 1.

data completeness: quantified as the proportion of complete outcome data per test and condition (criterion: ≥80% complete data)

Data recording during all planned tests in the virtual reality and non-virtual reality conditions within the single assessment session on Day 1.
Percentage increase in assessment time with virtual reality compared with no virtual reality
時間枠:From the start to the end of each assessment (mobility and balance assessments) in each condition (virtual reality and non-virtual reality) during the single assessment session on Day 1.

assessment burden: reflected by total assessment time, considered acceptable if VR assessments required no more than 20% additional time compared to noVR conditions

From the start to the end of each assessment (mobility and balance assessments) in each condition (virtual reality and non-virtual reality) during the single assessment session on Day 1.
Number of participants experiencing adverse events during assessment
時間枠:From the start of the assessment session until 15 minutes after its completion on Day 1, including both virtual reality and non-virtual reality assessments.

Number of participants experiencing at least one adverse event during the assessment session, including both virtual reality and non-virtual reality conditions, or within 15 minutes after its completion.

From the start of the assessment session until 15 minutes after its completion on Day 1, including both virtual reality and non-virtual reality assessments.
Virtual Reality Sickness Questionnaire scores (VRSQ)
時間枠:single session, Immediately after completion of the virtual reality session on Day 1.

The VRSQ is a modified version of the Simulator Sickness Questionnaire and consists of nine items assessing symptoms of VR-induced discomfort. These items are grouped into two subdomains: oculomotor discomfort (items 1-4) and disorientation (items 5-9). Each item is rated on a four-point Likert scale ranging from 0 ("not at all") to 3 ("severe"). Subscale scores are normalized and combined to yield a total VRSQ score, with higher scores indicating greater VR sickness.

single session, Immediately after completion of the virtual reality session on Day 1.

二次結果の測定

結果測定
メジャーの説明
時間枠
iGroup Presence Questionnaire subscale scores
時間枠:single session, Immediately after completion of the virtual reality session on Day 1.

The IPQ assesses different dimensions of presence and consists of items grouped into four subscales: General Presence (GP), Spatial Presence (SP), Involvement (INV), and Experienced Realism (ER). Items are rated on a seven-point Likert scale ranging from 0 to 6, with higher scores indicating a stronger sense of presence within the virtual environment.

single session, Immediately after completion of the virtual reality session on Day 1.
Within-participant difference in Mini-BESTest total score between virtual reality and non-virtual reality conditions
時間枠:single session; During Mini-BESTest administration in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.

The Mini-Balance Evaluation Systems Test (Mini-BESTest) is a standardized clinical assessment of dynamic balance and a shortened version of the Balance Evaluation Systems Test (BESTest). It consists of 14 items covering four balance domains: anticipatory postural adjustments (items 1-3), reactive postural control (items 4-6), sensory orientation (items 7-9), and dynamic gait (items 10-14) (A.3). Each item is scored on a three-level ordinal scale (0-2), resulting in a maximum total score of 28 points, with higher scores indicating better balance performance. For items requiring bilateral assessment (items 3 and 6), the lower score was retained.

single session; During Mini-BESTest administration in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.
Within-participant difference in single-task and cognitive dual-task Timed Up and Go completion time between virtual reality and non-virtual reality conditions
時間枠:single session; During single-task and cognitive dual-task Timed Up and Go testing in both conditions (virtual reality and non-virtual reality) within the single assessment session on Day 1.

Participants are instructed to stand up from a chair, walk three meters at a safe and comfortable speed, cross a marked line on the floor, turn around, walk back to the chair, and sit down. The time required to complete the task was recorded in seconds. In addition to the standard single-task TUG, a cognitive dual-task version was administered. During the dual-task TUG, participants were asked to count backwards by threes from a randomly selected number between 20 and 100 while performing the motor task. Both single-task and dual-task TUG were performed under noVR and VR conditions, resulting in four TUG conditions in total.

single session; During single-task and cognitive dual-task Timed Up and Go testing in both conditions (virtual reality and non-virtual reality) within the single assessment session on Day 1.
Within-participant difference in comfortable walking speed between virtual reality and non-virtual reality conditions
時間枠:single session; During comfortable walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1

The 10-meter walk test was used to assess participants' walking speed. Participants started at the 0-meter (m) mark and walked to the 10 m mark. Timing was performed with a stop watch over the central 6 m, beginning 2 m after the start line and ending 2 m before the end line, to allow for acceleration and deceleration phases and to capture steady-state walking speed. Walking speed (m/s) was calculated by dividing the distance (6 m) by the recorded time (seconds). Two trials were performed at the participant's comfortable walking speed, followed by two trials at their fastest walking speed, according to standardized instructions.

For each speed condition, the two trials were averaged, and the resulting comfortable and fast gait speeds were documented in meters per second.

single session; During comfortable walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1
Within-participant difference in fast walking speed between virtual reality and non-virtual reality conditions
時間枠:single session; During fast walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.

The 10-meter walk test was used to assess participants' walking speed. Participants started at the 0-meter (m) mark and walked to the 10 m mark. Timing was performed with a stop watch over the central 6 m, beginning 2 m after the start line and ending 2 m before the end line, to allow for acceleration and deceleration phases and to capture steady-state walking speed. Walking speed (m/s) was calculated by dividing the distance (6 m) by the recorded time (seconds). Two trials were performed at the participant's comfortable walking speed, followed by two trials at their fastest walking speed, according to standardized instructions.

For each speed condition, the two trials were averaged, and the resulting comfortable and fast gait speeds were documented in meters per second.

single session; During fast walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Bart Jansen, PhD、ETRO, Vrije Universiteit Brussel

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年2月17日

一次修了 (実際)

2025年2月28日

研究の完了 (実際)

2025年2月28日

試験登録日

最初に提出

2026年10月19日

QC基準を満たした最初の提出物

2026年11月5日

最初の投稿 (実際)

2026年11月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data underlying the results reported in publications arising from this study will be made available by the corresponding author upon reasonable request following publication.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する